Cantor Fitzgerald Reaffirms “Neutral” Rating for Aspira Women’s Health (NASDAQ:AWH)

Cantor Fitzgerald restated their neutral rating on shares of Aspira Women’s Health (NASDAQ:AWH) in a report published on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $3.30 price target on the stock.

Separately, StockNews.com raised shares of Aspira Women’s Health from a sell rating to a hold rating in a report on Wednesday, April 3rd.

Aspira Women’s Health Trading Up 6.2 %

AWH opened at $3.42 on Wednesday. The company has a 50 day moving average of $3.84 and a 200 day moving average of $4.13. The company has a market cap of $42.22 million, a PE ratio of -0.28 and a beta of 1.61. Aspira Women’s Health has a 12 month low of $2.31 and a 12 month high of $6.75.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Atria Wealth Solutions Inc. boosted its holdings in Aspira Women’s Health by 42.1% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 67,151 shares of the company’s stock valued at $39,000 after purchasing an additional 19,900 shares during the period. JPMorgan Chase & Co. boosted its holdings in Aspira Women’s Health by 126.3% in the 1st quarter. JPMorgan Chase & Co. now owns 64,839 shares of the company’s stock valued at $67,000 after purchasing an additional 36,189 shares during the period. Sawtooth Solutions LLC boosted its holdings in Aspira Women’s Health by 144.6% in the 1st quarter. Sawtooth Solutions LLC now owns 67,983 shares of the company’s stock valued at $71,000 after purchasing an additional 40,195 shares during the period. Private Advisor Group LLC boosted its holdings in Aspira Women’s Health by 361.8% in the 1st quarter. Private Advisor Group LLC now owns 69,697 shares of the company’s stock valued at $73,000 after purchasing an additional 54,603 shares during the period. Finally, Northeast Financial Consultants Inc bought a new position in Aspira Women’s Health in the 3rd quarter valued at $126,000. 12.19% of the stock is owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.